Recipharm Acquires Portuguese CDMO, GenIbet, Boosting Biologics Offering

Published on: 

Recipharm will build up its biologics service offering with the acquisition of GenIbet.

On Feb. 1, 2022, Recipharm announced the acquisition of GenIbet, a Portuguese contract development and manufacturing organization specializing in clinical trial manufacturing and the manufacture of novel modalities, including viral vectors, RNA, and microbiome. The acquisition bolsters Recipharm’s biologics offering, specifically drug substance manufacturing of novel advanced therapy medicinal products.

GenIbet currently focuses on the preclinical and Phase I stages and offers process development services, including the development of new production routes not previously established. Under the deal, Genlbet will provide Recipharm with a platform from which to build its capabilities in new biologics modalities.

“This acquisition is an important step for us in growing our biologics business. We look forward to working closely with the GenIbet team, building links across the wider Recipharm organization to make this business a huge success,” said Marc Funk, CEO of Recipharm, in a company press release.


“Combining our experience and expertise with Recipharm’s capabilities and market reach will make a significant difference for customers on an international scale,” said Raquel Fortunato, CEO at GenIbet, in the press release.

Source: Recipharm